Baudax Bio announced that Anjeso™ (meloxicam injection) is now available for ordering and delivery to customers. The treatment is approved for the management of moderate to severe pain, alone or in combination with non-nonsteroidal anti-inflammatory drugs in adult patients.
Anjeso is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory, and antipyretic properties. The product contains 30mg of meloxicam per mL and is administered as a once-daily intravenous bolus injection. Patients must be well hydrated prior to administration to reduce the risk of renal toxicity.
Because of the delayed onset of analgesia, Anjeso alone is not recommended for use when rapid onset of analgesia is required. In 2 clinical studies, the median time to meaningful pain relief was found to be 2 to 3 hours after Anjeso administration. Some patients may require administration of a short-acting, non-NSAID, immediate-release analgesic for adequate analgesia over the 24-hour dosing interval.
Regarding safety, the most common adverse reactions reported with treatment included constipation, increased gamma-glutamyl transferase, and anemia. As with other NSAIDs, Anjeso carries a Boxed Warning about the potential risk of serious cardiovascular and gastrointestinal events associated with therapy.
“We are delighted to announce the availability of Anjeso for ordering and delivery in the US,” said Gerri Henwood, President and CEO of Baudax Bio. “We believe Anjeso is a major advancement in the physician’s armamentarium for managing moderate to severe pain for a wide variety of surgical procedures.”
The product is supplied as 30mg/mL of meloxicam in single-dose vials. A full commercial launch of Anjeso is expected by June 2020.
For more information visit anjeso.com.
This article originally appeared on MPR